Re-testing of predictive biomarkers on surgical breast cancer specimens is clinically relevant.
Stephanie RobertsonCaroline RönnlundJana de BonifaceJohan HartmanPublished in: Breast cancer research and treatment (2019)
The agreement of HER2 and Ki67 between CNB and paired surgical specimen in primary breast cancer is insufficient. Limited agreement of surrogate tumor subtypes indicates a significant clinical value of biomarker re-testing on surgical specimens.